Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.

Indication Tooltip

LORBRENA ® (lorlatinib) is a prescription medicine that is used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of your body.

Your healthcare provider will perform a test to make sure that LORBRENA is right for you.

It is not known if LORBRENA is safe and effective in children.

ANAPLASTIC LYMPHOMA KINASE (ALK)+ NON-SMALL CELL LUNG CANCER (NSCLC)

magnifying glass icon

Our Understanding of ALK+ NSCLC Is Evolving

For years, lung cancer was thought to be a single illness linked to smoking. But science has taught us that lung cancer is a complex disease with many types and subtypes. It can develop in men and women of different ages and races, regardless of whether they've ever smoked.

One subtype of lung cancer is ALK+ NSCLC. Living with ALK+ NSCLC can be challenging and sometimes discouraging, especially if it continues to grow or spread (known as "progression"). If it does, you should know that there are certain therapies called ALK inhibitors that may help you. They may be effective as the first therapy you receive, and some of them may be effective even after you've already taken one or more prior ALK inhibitors.

The ALK Fusion Gene

Everyone has the ALK gene in each of their cells. If part of the ALK gene breaks off and reattaches the wrong way, it can create an ALK fusion gene. This may cause the cell to multiply out of control, resulting in cancer growth.

Because there are ALK inhibitor treatments available, doctors can create treatment plans specifically for people with ALK+ NSCLC that has spread (or "metastasized").

 

lungs icon

NSCLC accounts for 80% to 85% of all lung cancer cases; 3% to 5% of people with NSCLC test positive for the ALK fusion gene.

 

 

Hear a real patient's diagnosis experience

Image of Jeff and Rhonda

"I remember clearly that day when they called us in to tell us the results of the biomarker testing." -Jeff, LORBRENA patient

Watch Jeff's story

Turn to Pfizer Oncology Together™ to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.